Abnormal Uterine Bleeding in a 52-Year-Old with Obesity and Diabetes
A 52-year-old G2P2 presents with 8 months of irregular, heavy vaginal bleeding. She reports soaking through a pad every 2 hours for 3 days at a time, with clots, and no bleeding for 2–3 weeks between episodes. She has not had a period in 14 months by her report, but the bleeding has been ongoing. BMI 38, type 2 diabetes for 10 years (HbA1c 8.4%), hypertension, and she takes metformin and lisinopril. She has never used hormone therapy. Examination: BMI 38, no abdominal masses, speculum shows a closed cervix with blood in the vault, and bimanual exam reveals a slightly enlarged, mobile, nontender uterus. Office endometrial biopsy is attempted but the sample is insufficient for diagnosis.
1. What is your differential diagnosis, and how do you proceed after the insufficient biopsy?
Read the worked answer
The differential is broad: endometrial hyperplasia (with or without atypia), endometrial carcinoma, anovulatory bleeding from perimenopause, submucosal fibroids or polyps, and, less likely, cervical or vaginal pathology. Her risk factors for endometrial cancer are substantial - obesity, long-standing type 2 diabetes, hypertension, and age over 50 with abnormal bleeding. The insufficient office biopsy is not reassuring; it must be resolved.
Next steps: transvaginal ultrasound to assess endometrial thickness and look for a focal lesion. In a postmenopausal woman with bleeding, an endometrial thickness of 4 mm or less has a high negative predictive value, but given her ongoing bleeding and risk factors, imaging alone is not sufficient. She needs a tissue diagnosis. Options: repeat office biopsy with a Pipelle, or - preferably - hysteroscopy with directed biopsy and dilation and curettage, which allows visualization of focal lesions and adequate sampling. Given the insufficient first sample, proceed to hysteroscopy with D&C.
Also check CBC (anemia from chronic bleeding), ferritin, and consider coagulation studies. Do not attribute the bleeding to perimenopause until malignancy is excluded.
2. Hysteroscopy and biopsy show endometrial intraepithelial neoplasia (atypical hyperplasia). She wants to avoid hysterectomy. How do you counsel her, and what determines whether conservative management is reasonable?
Read the worked answer
Endometrial intraepithelial neoplasia (atypical hyperplasia) carries a substantial risk of concurrent or subsequent endometrial carcinoma - on the order of 25–40% - so hysterectomy is the standard recommendation, especially at age 52 when fertility is not a concern. She should be counseled clearly that conservative management is not the standard of care for her situation.
If she declines surgery: conservative management with high-dose progestin (levonorgestrel intrauterine system, or oral megestrol) can be considered only if (1) she understands and accepts the risk of progression, (2) she is a candidate for close surveillance with repeat endometrial sampling every 3–6 months, and (3) she has no evidence of invasive carcinoma on adequate sampling. Her obesity and diabetes make her a higher-risk surgical candidate, which is a legitimate consideration, but it does not eliminate the cancer risk.
Key counseling points: she must have a plan for definitive surgery if progression occurs; she needs weight optimization and glycemic control, which independently reduce risk; and she should understand that a negative repeat biopsy does not guarantee absence of cancer. If she chooses surgery, total hysterectomy with bilateral salpingo-oophorectomy is appropriate; lymph node assessment is not required for atypical hyperplasia alone unless invasive cancer is found.
3. She undergoes total laparoscopic hysterectomy with bilateral salpingo-oophorectomy. Final pathology shows FIGO grade 1 endometrioid adenocarcinoma confined to the inner half of the myometrium, 2.5 cm, no lymphovascular invasion. What is her adjuvant management, and why?
Read the worked answer
This is stage IA, grade 1 endometrioid carcinoma with no adverse features (no LVSI, tumor under 50% myometrial invasion, size 2.5 cm). The recurrence risk is low, and adjuvant therapy - pelvic radiation or chemotherapy - is not indicated. She should be observed.
Reasoning: adjuvant radiation reduces local recurrence but does not improve overall survival in low-risk early-stage disease, and it adds toxicity. Chemotherapy is reserved for high-risk histologies or advanced stage. Her obesity and diabetes are relevant to surveillance and to future risk counseling but do not change the adjuvant decision.
Surveillance: history and physical every 3–6 months for 2–3 years, then every 6–12 months; counsel on vaginal bleeding or discharge, pelvic pain, and weight loss. Imaging and CA-125 are not routinely recommended for asymptomatic surveillance. Address modifiable risk factors - weight, glycemic control - because they affect overall health and possibly recurrence risk.